This trial studies melanoma patients' decision to have or to decline immunotherapy after surgery. Receiving treatment after surgery to try to reduce the risk of disease returning is called adjuvant treatment. Studying patients' decision about receiving treatment after surgery may help doctors identify factors that patients consider when deciding whether or not to receive adjuvant treatment and how patients feel about their decision after one year.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03843593.
PRIMARY OBJECTIVES:
I. Identify the factors patients consider in deciding whether or not to undergo adjuvant therapy.
II. Once patients make a decision either to undergo adjuvant therapy or not, assess their attitudes, satisfaction, and quality of life over the first year.
OUTLINE:
Patients watch a brief informational video over 4 minutes via a tablet computer (e.g., iPad) about the benefits and potential risks of accepting adjuvant treatment.
After completion of study, patients are followed up at 3, 6, 9, and 12 months.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorPaul B. Chapman
